We are live on
!
Find out more
JJ
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter
Est. Return
+2.72%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$4.41B
AUM Growth
+$26.8M
(+0.61%)
Cap. Flow
+$12.3M
Cap. Flow
% of AUM
0.28%
Top 10 Holdings %
Top 10 Hldgs %
98.88%
Holding
24
New
1
Increased
1
Reduced
3
Closed
2
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVRx
CVRX
|
+$14.4M |
| 2 |
Standard BioTools
LAB
|
+$753K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nano X Imaging
NNOX
|
+$1.27M |
| 2 |
Adicet Bio
ACET
|
+$838K |
| 3 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$711K |
| 4 |
HLSQ
Tessera Defense and Homeland Security Inc.
HLSQ
|
+$58.4K |
| 5 |
Apollomics
APLM
|
+$12.8K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 88.66% |
| 2 | Healthcare | 11.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Kenvue
KVUE
$34.6B
| $3.91B | 88.66% |
182,329,550
| – | – |
2023 Q4
1 quarter
|
|
2
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $78.3M | 1.77% |
3,670,516
| – | – |
2021 Q3
10 quarters
|
|
|
3
CVRx
CVRX
$35.7M
| $74.7M | 1.69% |
4,103,430
+607,855
| +17% | +$14.4M |
2021 Q3
10 quarters
|
|
4
Protagonist Therapeutics
PTGX
$8.82B
| $70.9M | 1.61% |
2,449,183
| – | – |
2021 Q3
10 quarters
|
|
5
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $54.3M | 1.23% |
166,812
| – | – |
2023 Q4
1 quarter
|
|
6
Legend Biotech
LEGN
$3.7B
| $45.7M | 1.04% |
814,586
| – | – |
2021 Q3
10 quarters
|
|
7
MeiraGTx Holdings
MGTX
$904M
| $40.3M | 0.91% |
6,641,064
| – | – |
2021 Q3
10 quarters
|
|
8
Nanobiotix
NBTX
$1.08B
| $36.6M | 0.83% |
5,623,816
| – | – |
2023 Q3
2 quarters
|
|
9
Neumora Therapeutics
NMRA
$66.6M
| $25.4M | 0.58% |
1,849,445
| – | – |
2023 Q3
2 quarters
|
|
10
Fate Therapeutics
FATE
$232M
| $24.8M | 0.56% |
3,379,064
| – | – |
2021 Q3
10 quarters
|
|
11
Procept Biorobotics
PRCT
$1B
| $17.7M | 0.4% |
357,939
| – | – |
2021 Q3
10 quarters
|
|
12
Xencor
XNCR
$1.74B
| $16.6M | 0.38% |
748,062
| – | – |
2021 Q4
9 quarters
|
|
13
Arrowhead Research
ARWR
$8.25B
| $7.08M | 0.16% |
247,598
| – | – |
2021 Q3
10 quarters
|
|
14
Vor Biopharma
VOR
$1.11B
| $2.55M | 0.06% |
53,733
| – | – |
2021 Q3
10 quarters
|
|
|
15
Nano X Imaging
NNOX
$40.1M
| $1.55M | 0.04% |
158,852
-158,852
| -50% | -$1.27M |
2021 Q4
9 quarters
|
|
16
Aldeyra Therapeutics
ALDX
$47.7M
| $980K | 0.02% |
299,669
| – | – |
2021 Q3
10 quarters
|
|
|
HLSQ
17
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
| $865K | 0.02% |
1,012
-111
| -10% | -$58.4K |
2021 Q3
10 quarters
|
|
|
18
Adicet Bio
ACET
$45.8M
| $857K | 0.02% |
22,780
-20,257
| -47% | -$838K |
2021 Q3
10 quarters
|
|
|
19
Standard BioTools
LAB
$248M
| $845K | 0.02% |
+311,967
| New | +$753K |
2024 Q1
0 quarters
|
|
20
DELISTED
Clearside Biomedical
CLSD
| $260K | 0.01% |
11,309
| – | – |
2022 Q4
5 quarters
|
|
|
TCON
21
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $36.1K | ﹤0.01% |
4,200
| – | – |
2021 Q3
10 quarters
|
|
22
Senseonics Holdings Inc
SENS
$428M
| $29K | ﹤0.01% |
2,731
| – | – |
2021 Q3
10 quarters
|
|
|
23
Apollomics
APLM
$63.5M
| – | – |
-133
| Closed | -$12.8K | – |
|
|
SLGC
24
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| – | – |
-281,052
| Closed | -$711K | – |
|
Similar funds
SEM
TI
GIM
QCMNJ
LOPW
HW
CCM
LWM
Johnson & Johnson's Q1 2024 Portfolio in Review
As of Q1 2024, Johnson & Johnson held 24 positions worth $4.41B, up 0.61% from $4.39B the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Johnson & Johnson's Q1 2024 filing shows 1 new, 1 increased, 3 reduced and 2 closed positions. Its largest new stake was Standard BioTools: 311,967 shares worth $845K. The largest sale was Nano X Imaging, an estimated $1.27M.
By sector, the portfolio is most concentrated in Consumer Staples at 89% of assets, down from 89% a quarter earlier, followed by Healthcare.
- Johnson & Johnson's largest Q1 2024 buy was Standard BioTools: 311,967 shares worth $845K.
- Johnson & Johnson added most to CVRx in Q1 2024, an estimated $14.4M increase.
- Johnson & Johnson's biggest Q1 2024 reduction was Nano X Imaging, cutting an estimated $1.27M.
- Johnson & Johnson fully exited SomaLogic, Inc. Class A Common Stock in Q1 2024, selling an estimated $711K.
- Johnson & Johnson's ten largest holdings make up 99% of its $4.41B portfolio in Q1 2024.
- Johnson & Johnson opened 1 new position and closed 2 in Q1 2024.
- Johnson & Johnson's portfolio value rose 0.61% quarter-over-quarter to $4.41B.
Based on Johnson & Johnson's 13F filing for Q1 2024, filed 10 May 2024.